MedPath

Full Circles Therapeutics Secures USPTO Patent for Revolutionary Circular Single-Stranded DNA Genome Editing Platform

• Full Circles Therapeutics has received USPTO patent allowance for its C4DNA™ GATALYST™ platform, enabling precise genome modification using circular single-stranded DNA without viral vectors.

• The technology offers significant advantages over traditional methods, including improved gene integration efficiency while minimizing immunogenicity, cytotoxicity, and off-target effects.

• The company is actively seeking licensing and partnership opportunities across biotechnology and pharmaceutical industries to advance applications in oncology, autoimmune diseases, and regenerative medicine.

Full Circles Therapeutics announced today that the United States Patent and Trademark Office (USPTO) has allowed its foundational patent titled "TARGETED GENOME MODIFICATION USING CIRCULAR SINGLE-STRANDED DNA." The Cambridge, Massachusetts-based biotechnology company specializes in next-generation genome engineering and has developed a platform that enables precise, efficient, and non-viral genome modification.
The newly patented technology utilizes circular single-stranded DNA (cssDNA) to overcome key challenges in genome engineering, providing a safer alternative to viral vectors and traditional double-stranded DNA (dsDNA) donors. This breakthrough improves gene integration efficiency while minimizing immunogenicity, cytotoxicity, and off-target effects.

Addressing Limitations of Current Gene Editing Technologies

The field of genome engineering has faced significant challenges with existing viral-based gene transfer methods. Lentiviral and adeno-associated virus (AAV) vectors present risks of unpredictable genomic integration, immunogenicity, and manufacturing complexities that have limited their therapeutic potential.
Full Circles' proprietary cssDNA-based technology, dubbed C4DNA™ GATALYST™ genome engineering platform, enables targeted transgene integration via homology-directed repair (HDR) without the risks associated with viral vectors. This approach significantly improves precision while reducing toxicity, making it particularly suitable for next-generation, virus-free therapeutic applications.
"The allowance of this patent is a significant milestone in advancing non-viral genome editing," said Richard Shan, co-founder and Chairman of Full Circles Therapeutics. "Our proprietary cssDNA platform offers a safer and more precise alternative for gene modification, paving the way for improved allogeneic cell therapies, CAR-NK and CAR-T therapies, and other transformative treatments."

Broad Applications in Cell and Gene Therapy

The technology has potential applications across multiple therapeutic areas, including cell and gene therapy, regenerative medicine, and biomedical research. The platform's modular and scalable nature makes it adaptable to various genetic modification needs.
Howard Wu, co-founder and CSO of Full Circles Therapeutics, emphasized the technology's versatility: "We believe C4DNA™ GATALYST™ technology has immense potential across oncology, autoimmune diseases, regenerative medicine, and beyond. By offering this platform for licensing, we aim to empower other innovators to enhance their gene editing capabilities and advance safer, faster, more affordable and effective therapies."

Licensing and Partnership Opportunities

To maximize the impact of their technology, Full Circles Therapeutics is actively seeking licensing and partnership opportunities across the biotechnology and pharmaceutical industries. This strategic approach aims to accelerate innovation and expand the application of their cssDNA platform.
The company believes that collaborative efforts will help realize the full potential of this technology in addressing unmet medical needs and developing next-generation therapies. Interested parties can contact Flora Zhang, Director of Communications at Full Circles Therapeutics, for licensing inquiries.

Technical Advantages of Circular Single-Stranded DNA

The C4DNA™ GATALYST™ platform represents a significant advancement in genome engineering technology. Unlike traditional methods, circular single-stranded DNA offers several technical advantages:
  1. Enhanced safety profile with reduced immunogenicity compared to viral vectors
  2. Improved precision in targeted gene integration
  3. Reduced off-target effects and cytotoxicity
  4. Scalable manufacturing process
  5. Greater flexibility in genetic payload capacity
These advantages position the technology as a promising solution for developing safer and more effective gene therapies, particularly in applications where precision and safety are paramount.

Future Implications for Gene Therapy

As the demand for advanced gene editing technologies continues to grow, Full Circles Therapeutics' cssDNA platform could play a pivotal role in shaping the future of genetic medicine. The non-viral approach addresses many of the concerns that have limited the widespread adoption of gene therapy, potentially expanding treatment options for patients with genetic disorders, cancer, and other conditions.
The patent allowance represents not only a significant achievement for Full Circles Therapeutics but also a promising development for the broader field of genome engineering. As the company moves forward with licensing and partnerships, the impact of this technology could extend far beyond its current applications, potentially transforming how genetic modifications are performed in both research and clinical settings.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

IDEAYA Biosciences Licenses DLL3-Targeting ADC from Hengrui Pharma in $1B Deal

IDEAYA Biosciences has secured an exclusive license from Hengrui Pharma for SHR-4849, a DLL3-targeting antibody-drug conjugate (ADC), outside of Greater China.
SHR-4849 is currently in Phase 1 trials and has demonstrated promising antitumor activity in preclinical studies, particularly in small cell lung cancer (SCLC).

Focused Ultrasound Enhances CRISPR Precision for Genetic Disorder Treatment

Researchers have developed an ultrasound-controlled CRISPR system for precise gene editing, enhancing control over gene activation and silencing.
The new method uses focused ultrasound to initiate temperature changes at specific sites, activating CRISPR proteins for targeted DNA modification.

FDA Approves PTC Therapeutics' Upstaza for AADC Deficiency

The FDA has approved Upstaza (eladocagene exuparvovec), a gene therapy developed by PTC Therapeutics, for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC) deficiency.
Upstaza is administered directly into the brain via neurosurgical procedure, offering a novel approach to address the underlying genetic defect of AADC deficiency.

FDA Approves KEBILIDI, First Brain-Delivered Gene Therapy for AADC Deficiency

The FDA has approved KEBILIDI (eladocagene exuparvovec-tneq), a gene therapy for aromatic l-amino acid decarboxylase (AADC) deficiency, marking the first brain-delivered gene therapy in the U.S.
KEBILIDI, developed by PTC Therapeutics, is a gene replacement therapy administered directly to the brain to restore dopamine production in patients with AADC deficiency.

FDA Approves PTC Therapeutics' Kebilidi, First Direct-to-Brain Gene Therapy

The FDA has approved PTC Therapeutics' Kebilidi (eladocagene exuparvovec-tneq) for aromatic L-amino acid decarboxylase (AADC) deficiency, a rare genetic disorder.
Kebilidi is the first gene therapy approved by the FDA that is administered directly into the brain, specifically targeting the putamen region.

FDA Approves Kebilidi, First Brain-Delivered Gene Therapy for AADC Deficiency

The FDA has approved Kebilidi (eladocagene exuparvovec), a gene therapy for AADC deficiency, marking the first brain-delivered gene therapy approved in the US.
Kebilidi replaces the mutated DDC gene, enabling dopamine synthesis and addressing severe motor and neurological symptoms in children and adults with AADC deficiency.

ClearPoint Neuro's SmartFlow Cannula Receives FDA Approval for Direct Brain Gene Therapy Delivery

ClearPoint Neuro's SmartFlow Neuro Cannula receives FDA De Novo marketing authorization, marking the first device approved for direct brain gene therapy delivery.
The device is specifically approved for intraputaminal administration of PTC Therapeutics' KEBILIDI™ to treat aromatic L-amino acid decarboxylase (AADC) deficiency.

FDA Approves PTC Therapeutics' Gene Therapy KEBILIDI for AADC Deficiency

The FDA has granted accelerated approval to KEBILIDI (eladocagene exuparvovec-tneq), a gene therapy for AADC deficiency, marking the first FDA-approved gene therapy directly administered to the brain.
KEBILIDI, developed by PTC Therapeutics, is indicated for both children and adults with AADC deficiency, addressing a critical unmet need across the spectrum of disease severity.

FDA Clears IND for Calidi Biotherapeutics' CLD-101 in High-Grade Glioma

The FDA has cleared Northwestern University's IND application for Calidi Biotherapeutics' CLD-101, a stem cell-based oncolytic virus therapy.
A Phase 1b/2 trial will evaluate multiple doses of CLD-101 in patients with newly diagnosed high-grade glioma, commencing in late 2024.

CRISPR Technology Shows Promise Across Diverse Clinical Applications

CRISPR-Cas9 gene editing has achieved a significant milestone with FDA approval of Casgevy for sickle cell disease and transfusion-dependent beta thalassemia.
Clinical trials are underway for CRISPR-based therapies targeting urinary tract infections, hereditary transthyretin amyloidosis, hereditary angioedema, and cardiovascular diseases.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy